Cargando…

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)

OBJECTIVE: We characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied whether those fluctuations are related to the early C-peptide response to oral glucose. RESEARCH DESIGN AND METHODS: Oral glucose tolerance tests (OGTTs) from differing states of glycemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosenko, Jay M., Skyler, Jay S., Krischer, Jeffrey P., Greenbaum, Carla J., Mahon, Jeffrey, Rafkin, Lisa E., Cuthbertson, David, Cowie, Catherine, Herold, Kevan, Eisenbarth, George, Palmer, Jerry P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	New Methodologies and Databases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279562/ https://www.ncbi.nlm.nih.gov/pubmed/20682683 http://dx.doi.org/10.2337/db10-0534

Ejemplares similares

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver operating characteristic analysis
por: Xu, Ping, et al.
Publicado: (2012)

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2010)

Long-Term Outcome of Individuals Treated With Oral Insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial
por: Vehik, Kendra, et al.
Publicado: (2011)

Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies
por: Yu, Liping, et al.
Publicado: (2012)

Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood
por: Vehik, Kendra, et al.
Publicado: (2011)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Feature ranking based on synergy networks to identify prognostic markers in DPT-1
por: Adl, Amin Ahmadi, et al.
Publicado: (2013)

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

George S. Eisenbarth: Insulin and Type 1 Diabetes
por: Pugliese, Alberto, et al.
Publicado: (2013)

Impact of Diabetes Susceptibility Loci on Progression From Pre-Diabetes to Diabetes in At-Risk Individuals of the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Butty, Vincent, et al.
Publicado: (2008)

The Compelling Case for Anti-CD3 in Type 1 Diabetes
por: Skyler, Jay S.
Publicado: (2013)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

Diabetic Subjects Diagnosed Through the Diabetes Prevention Trial–Type 1 (DPT-1) Are Often Asymptomatic With Normal A1C at Diabetes Onset
por: Triolo, Taylor M., et al.
Publicado: (2009)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
por: Russell, William E., et al.
Publicado: (2023)

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited
por: Atkinson, Mark A., et al.
Publicado: (2011)

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
por: Nathan, Brandon M., et al.
Publicado: (2017)

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care 2019;42:2228–2236
por: Sims, Emily K., et al.
Publicado: (2020)

Resistance Versus Aerobic Exercise: Acute effects on glycemia in type 1 diabetes
por: Yardley, Jane E., et al.
Publicado: (2013)

Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood
por: Kahkoska, Anna R, et al.
Publicado: (2020)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Performance of HbA(1c) as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth
por: Vehik, Kendra, et al.
Publicado: (2012)

A quantitative measure of treatment response in recent‐onset type 1 diabetes
por: Bundy, Brian N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hq3gelujutfjn4h5e10rfd36he